All samples will be pseudonymized and shipped to the Coordinating Study Laboratory and Biobank (WBE) in Essen or to the Central ctDNA Sequencing Laboratory in Cologne. Biomaterials including DNA, RNA and proteins will be extracted and subjected to genomic, epigenetic and proteomic analyses. Assay results will be reported to the central study data base for scientific analyses. In addition, biomarker results obtained by NGS-based panel sequencing of tumor- and plasma-derived DNA will be reported back to the clinical investigators of the AIO-TRK-0114 (MARBLE) study, and can be shared with the study patients.